Ascendis Pharma A/S (NASDAQ:ASND) Shares Gap Up to $119.22

Ascendis Pharma A/S (NASDAQ:ASND - Get Free Report) shares gapped up prior to trading on Monday . The stock had previously closed at $119.22, but opened at $139.65. Ascendis Pharma A/S shares last traded at $143.83, with a volume of 357,706 shares changing hands.

Wall Street Analyst Weigh In

Several equities research analysts recently weighed in on ASND shares. StockNews.com upgraded Ascendis Pharma A/S from a "sell" rating to a "hold" rating in a research note on Thursday, September 5th. Citigroup lowered their target price on shares of Ascendis Pharma A/S from $193.00 to $178.00 and set a "buy" rating for the company in a report on Wednesday, September 4th. Evercore ISI raised shares of Ascendis Pharma A/S to a "strong-buy" rating in a research report on Monday, August 26th. Oppenheimer raised shares of Ascendis Pharma A/S from a "market perform" rating to an "outperform" rating and set a $180.00 price target for the company in a research report on Thursday, September 5th. Finally, Stifel Nicolaus initiated coverage on shares of Ascendis Pharma A/S in a research note on Friday, May 31st. They issued a "buy" rating and a $200.00 price objective for the company. Two research analysts have rated the stock with a hold rating, twelve have given a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat, the stock currently has an average rating of "Moderate Buy" and an average price target of $187.08.

Ascendis Pharma A/S Stock Up 17.1 %

The stock has a market cap of $8.13 billion, a PE ratio of -14.52 and a beta of 0.63. The stock has a fifty day moving average of $132.51 and a 200-day moving average of $136.47.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently modified their holdings of the stock. Vestal Point Capital LP acquired a new stake in shares of Ascendis Pharma A/S during the fourth quarter worth $78,719,000. Price T Rowe Associates Inc. MD lifted its stake in shares of Ascendis Pharma A/S by 23.3% in the 1st quarter. Price T Rowe Associates Inc. MD now owns 1,781,926 shares of the biotechnology company's stock worth $269,374,000 after acquiring an additional 336,976 shares during the period. Acadian Asset Management LLC lifted its stake in shares of Ascendis Pharma A/S by 1,461.1% in the 1st quarter. Acadian Asset Management LLC now owns 250,492 shares of the biotechnology company's stock worth $37,849,000 after acquiring an additional 234,446 shares during the period. Avoro Capital Advisors LLC boosted its holdings in shares of Ascendis Pharma A/S by 5.8% in the second quarter. Avoro Capital Advisors LLC now owns 4,196,661 shares of the biotechnology company's stock valued at $572,341,000 after acquiring an additional 229,995 shares in the last quarter. Finally, Westfield Capital Management Co. LP increased its stake in shares of Ascendis Pharma A/S by 6.0% during the fourth quarter. Westfield Capital Management Co. LP now owns 4,030,634 shares of the biotechnology company's stock worth $507,658,000 after acquiring an additional 228,457 shares during the period.

About Ascendis Pharma A/S

Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing therapies for unmet medical needs. It offers SKYTROFA for treating patients with growth hormone deficiency (GHD). The company is also developing a pipeline of three independent endocrinology rare disease product candidates in clinical development, as well as focuses on advancing oncology therapeutic candidates.